Patents by Inventor Ai Ching Lim

Ai Ching Lim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-IL-17 receptor A neutralizing antibodies
    Patent number: 9073999
    Abstract: The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and the antigen binding proteins, such as antibodies, that bind thereto and inhibit IL-17 ligand family members from binding to and activating IL-17 Receptor A or a receptor complex comprising IL-17 Receptor A.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: July 7, 2015
    Assignee: KIRIN-AMGEN, INC.
    Inventors: Joel Tocker, Christopher Mehlin, Ai Ching Lim
  • IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS
    Publication number: 20140356355
    Abstract: The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.
    Type: Application
    Filed: June 13, 2014
    Publication date: December 4, 2014
    Inventors: Joel E. Tocker, Jacques J. Peschon, David Fitzpatrick, James F. Smothers, Christopher Mehlin, Ai Ching Lim
  • Methods of treating psoriasis using IL-17 receptor A antibodies
    Patent number: 8790648
    Abstract: The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: July 29, 2014
    Assignee: Amgen Inc.
    Inventors: Joel Tocker, Jacques J. Peschon, David Fitzpatrick, James F. Smothers, Christopher Mehlin, Ai Ching Lim
  • INHIBITORS OF TYPE 2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS
    Publication number: 20140179896
    Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.
    Type: Application
    Filed: November 4, 2013
    Publication date: June 26, 2014
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Yan CHEN, Elena GETMANOVA, Martin C. WRIGHT, Alan S. HARRIS, Ai Ching LIM, Jochem GOKEMEIJER, Lin SUN, Michael WITTEKIND
  • METHODS AND COMPOSITIONS RELATING TO ANTI-IL-21 RECEPTOR ANTIBODIES
    Publication number: 20140105900
    Abstract: The present invention provides compositions and methods relating to antigen binding proteins against IL-21 receptor.
    Type: Application
    Filed: March 14, 2013
    Publication date: April 17, 2014
    Applicant: AMGEN INC.
    Inventors: Marc A. GAVIN, Ai Ching LIM
  • Methods of inhibiting type 2 vascular endothelial growth factor receptors using polypeptides
    Patent number: 8609613
    Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.
    Type: Grant
    Filed: July 18, 2012
    Date of Patent: December 17, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Chen, Elena Getmanova, Martin C. Wright, Alan S. Harris, Ai Ching Lim, Jochem Gokemeijer, Lin Sun, Michael Wittekind
  • Nucleic acid encoding 10FN3 polypeptide inhibitors of Type 2 vascular endothelial growth factor receptors
    Patent number: 8324362
    Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: December 4, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Chen, Elena Getmanova, Martin C. Wright, Alan S. Harris, Ai Ching Lim, Jochem Gokemeijer, Lin Sun, Michael Wittekind
  • INHIBITORS OF TYPE 2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS
    Publication number: 20120283184
    Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.
    Type: Application
    Filed: July 18, 2012
    Publication date: November 8, 2012
    Applicant: Bristol-Myers Squibb Company
    Inventors: Yan Chen, Elena Getmanova, Martin C. Wright, Alan S. Harris, Ai Ching Lim, Jochem Gokemeijer, Lin Sun, Michael Wittekind
  • IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS
    Publication number: 20120251547
    Abstract: The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.
    Type: Application
    Filed: May 15, 2012
    Publication date: October 4, 2012
    Applicant: Amgen, Inc.
    Inventors: Joel TOCKER, Jacques J. Peschon, David Fitzpatrick, James F. Smothers, Christopher Mehlin, Ai Ching Lim
  • Inhibitors of type 2 vascular endothelial growth factor receptors
    Patent number: 7858739
    Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.
    Type: Grant
    Filed: June 5, 2006
    Date of Patent: December 28, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Chen, Elena Getmanova, Martin C. Wright, Alan S. Harris, Ai Ching Lim, Jochem Gokemeijer, Lin Sun, Michael Wittekind
  • INHIBITORS OF TYPE 2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS
    Publication number: 20100310549
    Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.
    Type: Application
    Filed: May 26, 2010
    Publication date: December 9, 2010
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: YAN CHEN, ELENA GETMANOVA, MARTIN C. WRIGHT, ALAN S. HARRIS, AI CHING LIM, JOCHEM GOKEMEIJER, LIN SUN, MICHAEL WITTEKIND
  • Pharmacokinetic modulation and compositions for modified FN3 polypeptides
    Patent number: 7847062
    Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: December 7, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Chen, Elena Getmanova, Martin C. Wright, Alan S. Harris, Ai Ching Lim, Jochem Gokemeijer, Lin Sun, Michael Wittekind
  • ANTI-IL-17 RECEPTOR A NEUTRALIZING ANTIBODIES
    Publication number: 20100292442
    Abstract: The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and the antigen binding proteins, such as antibodies, that bind thereto and inhibit IL-17 ligand family members from binding to and activating IL-17 Receptor A or a receptor complex comprising IL-17 Receptor A.
    Type: Application
    Filed: May 21, 2010
    Publication date: November 18, 2010
    Applicant: AMGEN , INC.
    Inventors: JOEL TOCKER, CHRISTOPHER MEHLIN, AI CHING LIM
  • Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
    Patent number: 7767206
    Abstract: The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and the antigen binding proteins, such as antibodies, that bind thereto and inhibit IL-17 ligand family members from binding to and activating IL-17 Receptor A or a receptor complex comprising IL-17 Receptor A.
    Type: Grant
    Filed: September 27, 2007
    Date of Patent: August 3, 2010
    Assignee: Amgen Inc.
    Inventors: Joel Tocker, Christopher Mehlin, Ai Ching Lim
  • IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS
    Publication number: 20100028345
    Abstract: The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.
    Type: Application
    Filed: October 1, 2007
    Publication date: February 4, 2010
    Applicant: AMGEN INC.
    Inventors: Joel Tocker, Jacques J. Peschon, David Fitzpatrick, James F. Smothers, Christopher Mehlin, Ai Ching Lim
  • Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
    Publication number: 20080221307
    Abstract: The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and the antigen binding proteins, such as antibodies, that bind thereto and inhibit IL-17 ligand family members from binding to and activating IL-17 Receptor A or a receptor complex comprising IL-17 Receptor A.
    Type: Application
    Filed: September 27, 2007
    Publication date: September 11, 2008
    Applicant: Amgen, Inc.
    Inventors: Joel Tocker, Christopher Mehlin, Ai Ching Lim
  • Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
    Publication number: 20080220049
    Abstract: The present disclosure relates to novel sustained-release intraocular drug delivery systems and improvements in the treatment of retinopathies. In particular, fibronectin scaffold domain proteins that selectively inhibit VEGFR-2 are contemplated.
    Type: Application
    Filed: August 17, 2007
    Publication date: September 11, 2008
    Applicant: Adnexus, A Bristol-Myers Squibb R&D Company
    Inventors: Yan Chen, Elena Getmanova, Martin C. Wright, Alan S. Harris, Ai Ching Lim, Jochem Gokemeijer, Lin Sun, Michael Wittekind
  • Erythropoietin receptor agonists
    Publication number: 20080124340
    Abstract: Antibodies that bind erythropoietin receptor are provided. Methods of making and using such antibodies are also provided. Kits containing such antibodies are also provided.
    Type: Application
    Filed: April 13, 2007
    Publication date: May 29, 2008
    Inventors: Luis G. Borges, Randal R. Ketchem, Ai Ching Lim, Christopher Mehlin, Hongxing Zhou